NUVATION BIO INC
NUVATION BIO INC is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of cancer and other autoimmune diseases.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Nuvation Bio's stock with a target price of $8.25, indicating good potential for growth.
Financial Health
NuVation Bio is generating modest revenue and profits, but cash flow appears strong.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NUVB
Injectable Drug Innovation Opportunities 2025
The FDA's approval of an at-home injectable version of Eisai and Biogen's Alzheimer's drug, Leqembi, simplifies treatment for patients and caregivers. This development highlights a growing trend toward patient-centric care, creating investment opportunities in companies that specialize in innovative drug delivery systems and at-home therapeutic technologies.
Published: August 31, 2025
Explore BasketTargeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: August 11, 2025
Explore BasketLottery Tickets
These visionary companies are betting it all on game-changing innovations that could revolutionize entire industries. Hand-selected by our analysts, each represents a high-risk, high-reward opportunity with potential for explosive growth if their breakthrough technologies succeed.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Ahead
Upcoming trial readouts and regulatory steps can act as catalysts for valuation, though outcomes are uncertain and can drive volatility.
R&D‑Driven Progress
The company’s value depends on scientific progress and development execution; this can offer upside but also increases cash‑burn and execution risk.
Partnership Potential
Licensing or collaborations can provide funding and validation, but depend on successful data and mutual strategic fit; terms and timing vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
